As part of OICR’s executive team, she develops and implements strategic priorities across the Institute’s translational cancer research programs. She leads engagement and communications strategies with a broad range of provincial, national and international partners. Through the Implementation Science program, she promotes the uptake of evidence-based practice and research into use by policymakers and healthcare providers.

As the Executive Director of the new Canadian Pediatric Cancer Consortium, she is establishing a multi-stakeholder network to support pediatric cancer research and promote health system change leading to better outcomes and quality of life for all Canadian children with cancer.

She received a degree in Life Sciences from Queen’s University and a PhD in Immunology from the University of Toronto. She received postdoctoral training at Massachusetts General Hospital and Harvard University where she studied the molecular pathways involved in the development of leukemia and lymphoma in children. Prior to her role at OICR, she held leadership positions at the National Cancer Institute of Canada and the Canadian Cancer Society.

She is currently a member of a number of boards and advisory committees, including the Canadian Institutes of Health Research, North York General Hospital, The Canadian Cancer Trials Group and various other research, healthcare and community organizations.